DOCSLIB.ORG

Touro Infirmary New Orleans List of Charges

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Touro Infirmary New Orleans List of Charges LCMC Health is committed to helping patients understand and prepare for the cost of their care. LCMC Health provides a list of charges for services provided at our facilities; however, a patient’s out-of-pocket responsibility for these charges will vary, depending on their insurance coverage and benefit plan. We understand that it is confusing for a patient to navigate through the many factors involved in their final cost. Please contact our Financial Assistance staff at 504.702.3500 with any questions about a future service or a bill you have received. Service Description CPT/HCPCS Code Charge 0.45 % NACL WITH KCL 20 MEQ 20 MEQ/L SOLP 1,000 ML J3480 $26.60 3D REPORT WITH WORKSTATION 76377 $1,765.00 3D REPORT WITHOUT WORKSTATION 76376 $1,518.00 40 MEQ POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE J3480 $20.90 AB TITER FLOUR NON INFECT EA 86256 $23.00 ABACAVIR 300 MG TAB 30 EACH BLIST PACK $76.30 ABACAVIR 300 MG TAB 50 EACH BLIST PACK $76.33 ABATACEPT (WITH MALTOSE) 250 MG SOLR 1 EACH VIAL J0129 $9,541.80 ABCIXIMAB 10 MG/5 ML SOLN 5 ML VIAL J0130 $11,290.56 ABDOMINAL ASPIRATION OF FLUID SURROUNDING FETUS FO 59000 $911.00 ABDOMINAL ASPIRATION TO REDUCE AMOUNT OF FLUID SUR 59001 $1,451.00 ABDOMINAL INFUSION OF NORMAL SALINE INTO FETAL AMN 59070 $815.00 ABDOMINAL ULTRASOUND OF PREGNANT UTERUS 76812 $242.00 ABDOMINAL ULTRASOUND OF PREGNANT UTERUS (LESS THAN 76802 $526.00 ABDOMINAL ULTRASOUND OF PREGNANT UTERUS SINGLE OR 76801 $792.00 ABDOMINAL ULTRASOUND OF PREGNANT UTERUS SINGLE OR 76805 $840.00 ABDOMINAL ULTRASOUND OF PREGNANT UTERUS SINGLE OR 76811 $825.00 ABDOMINAL ULTRASOUND PREGNANT UTERUS (GREATER OR E 76810 $714.00 ACAMPROSATE 333 MG TBEC 50 EACH BLIST PACK $7.87 ACARBOSE 25 MG TAB 100 EACH BOTTLE $6.84 ACE - ANGIO CONVERTING ENZYME 82164 $211.00 ACEBUTOLOL 200 MG CAP 50 EACH BLIST PACK $8.22 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) SOLN 100 J0131 $396.72 ACETAMINOPHEN 120 MG SUPP 1 EACH BOX $2.95 ACETAMINOPHEN 32 MG/ML SYRG 2.5 ML SYRINGE $47.55 ACETAMINOPHEN 325 MG SUPP 1 EACH BOX $1.50 ACETAMINOPHEN 325 MG SUPP 12 EACH BOX $4.98 ACETAMINOPHEN 325 MG TAB 100 EACH BLIST PACK $0.49 ACETAMINOPHEN 325 MG TAB 100 EACH BOTTLE $0.49 ACETAMINOPHEN 325 MG TAB 100 EACH BOX $0.49 ACETAMINOPHEN 325 MG TAB 750 EACH BLIST PACK $0.48 ACETAMINOPHEN 500 MG TAB 1,000 EACH BOTTLE $0.15 ACETAMINOPHEN 500 MG TAB 100 EACH BLIST PACK $0.40 ACETAMINOPHEN 500 MG TAB 100 EACH PACKAGE $0.40 ACETAMINOPHEN 650 MG SUPP 50 EACH BOX $4.51 ACETAMINOPHEN 650 MG/20.3 ML SOLN 20.3 ML CUP $9.26 ACETAMINOPHEN-CODEINE 120-12 MG/5 ML SOLN 473 ML B $0.72 ACETAMINOPHEN-CODEINE 300-15 MG TAB 100 EACH BOTTL $2.31 ACETAMINOPHEN-CODEINE 300-30 MG TAB 1 EACH BLIST P $2.74 ACETAMINOPHEN-CODEINE 300-30 MG TAB 100 EACH BLIST $2.74 ACETAMINOPHEN-CODEINE 300-60 MG TAB 100 EACH BLIST $5.36 ACETAMINOPHEN-TYLENOL) 80307 $369.00 LCMC Health is committed to helping patients understand and prepare for the cost of their care. LCMC Health provides a list of charges for services provided at our facilities; however, a patient’s out-of-pocket responsibility for these charges will vary, depending on their insurance coverage and benefit plan. We understand that it is confusing for a patient to navigate through the many factors involved in their final cost. Please contact our Financial Assistance staff at 504.702.3500 with any questions about a future service or a bill you have received. Service Description CPT/HCPCS Code Charge ACETAZOLAMIDE 250 MG TAB 100 EACH BLIST PACK $15.91 ACETAZOLAMIDE 500 MG CPSR 100 EACH BOTTLE $32.63 ACETAZOLAMIDE 500 MG CPSR 30 EACH BLIST PACK $37.20 ACETAZOLAMIDE 500 MG SOLR 1 EACH VIAL J1120 $200.45 ACETIC ACID (BULK) 3 % LIQD 500 ML BOTTLE $193.80 ACETIC ACID (BULK) 5 % LIQD 500 ML BOTTLE $193.80 ACETIC ACID 0.25 % SOLN 1,000 ML BOTTLE $53.20 ACETIC ACID 2 % SOLN 15 ML BOTTLE $900.14 ACETIC ACID 2 % SOLN 15 ML DROP BTL $304.04 ACETIC ACID-HYDROCORTISONE 1-2 % DROP 10 ML DROP B $1,546.07 ACETYLCHOLINE BINDING AB 83519 $1,153.00 ACETYLCHOLINE BLOCK AB 83516 $130.00 ACETYLCHOLINE CHLORIDE 1 % (10 MG/ML) KIT 1 EACH K $859.03 ACETYLCHOLINE MODULATING AB 83516 $130.00 ACETYLCYSTEINE 200 MG/ML (20 %) SOLN 10 ML VIAL $110.81 ACETYLCYSTEINE 200 MG/ML (20 %) SOLN 30 ML VIAL J0132 $1,714.56 ACETYLCYSTEINE 200 MG/ML (20 %) SOLN 4 ML $29.16 ACETYLCYSTEINE 200 MG/ML (20 %) SOLN 4 ML VIAL $28.43 ACIDOPHILUS 100 MILLION CELL GRPK 1 EACH PACKET $15.44 ACIDOPHILUS 100 MILLION CELL GRPK 12 EACH PACKET $7.39 ACIDOPHILUS-SPOROGENES 35 MILLION- 25 MILLION CELL $1.60 ACNE SURGERY 10040 $266.00 ACTH LEVEL 82024 $324.00 ACTIVATED CHARCOAL 25 GRAM/120 ML SUSP 120 ML BOTT $9.12 ACTIVATED CHARCOAL-SORBITOL 25 GRAM/120 ML SUSP 12 $9.12 ACTIVITY THERAPY G0176 $1,090.00 ACUTE DIGESTIVE TRACT BLOOD LOSS IMAGING 78278 $873.00 ACYCLOVIR 200 MG CAP 100 EACH BLIST PACK $11.62 ACYCLOVIR 200 MG/5 ML SUSP 473 ML BOTTLE $17.88 ACYCLOVIR 400 MG TAB 100 EACH BLIST PACK $4.90 ACYCLOVIR 50 MG/ML SOLN 10 ML VIAL J0133 $102.60 ACYCLOVIR 50 MG/ML SOLN 20 ML VIAL J0133 $191.52 ADEFOVIR 10 MG TAB 30 EACH BOTTLE $430.16 ADENOSINE (DIAGNOSTIC) 3 MG/ML SOLN 30 ML VIAL J0153 $2,587.34 ADENOSINE 3 MG/ML SOLN 2 ML VIAL J0153 $28.26 ADENOSINE 3 MG/ML SYRG 2 ML SYRINGE J0153 $164.31 ADENOVIRUS ANTIGEN IMMUNOFLUORESCENT 87260 $522.00 ADMIN AND INTERPRETATION OF PATIENT FOCUSED HEALTH 96160 $92.00 ADMINISTRATION FLU VIRUS VACCINATION 90471 $124.00 ADMINISTRATION HEPATITIS B VACCINATION 90471 $154.00 ADMINISTRATION OF 1 VACCINE 90471 $106.00 LCMC Health is committed to helping patients understand and prepare for the cost of their care. LCMC Health provides a list of charges for services provided at our facilities; however, a patient’s out-of-pocket responsibility for these charges will vary, depending on their insurance coverage and benefit plan. We understand that it is confusing for a patient to navigate through the many factors involved in their final cost. Please contact our Financial Assistance staff at 504.702.3500 with any questions about a future service or a bill you have received. Service Description CPT/HCPCS Code Charge ADMINISTRATION OF DRUG FOR HELICOBACTER PYLORI 83014 $61.00 ADMINISTRATION OF INFLUENZA VIRUS VACCINE SUBSEQUE 90472 $106.00 ADMINISTRATION OF MEDICATION TO INDUCE VOMITING 99175 $320.00 ADMINISTRATION OF VACCINE 90472 $106.00 ADMINISTRATION PNEUMOCOCCAL VACCINATION 90471 $153.00 ADO-TRASTUZUMAB EMTANSINE 100 MG SOLR 1 EACH VIAL J9354 $26,847.00 ADO-TRASTUZUMAB EMTANSINE 160 MG SOLR 1 EACH VIAL J9354 $42,955.20 ADRENAL GLAND STIMULATION PANEL 80412 $2,577.00 AG DETECT LEGIONELLA EIA QL MULTI 87449 $461.00 AIR AND BONE CONDUCTION ASSESSMENT OF HEARING LOSS 92557 $330.00 AL HYD-MG TR-ALG AC-SOD BICARB 80-14.2 MG CHEW 100 $0.55 ALBUMIN, FLUID 82042 $58.00 ALBUMIN, HUMAN 25 % 25 % SOLP 100 ML FLEX CONT P9047 $1,064.00 ALBUMIN, HUMAN 25 % 25 % SOLP 50 ML FLEX CONT P9047 $532.00 ALBUMIN, HUMAN 5 % SOLP 250 ML FLEX CONT P9045 $338.20 ALBUTEROL 1.25 MG/3 ML NEBU 3 ML VIAL $12.61 ALBUTEROL 2 MG/5 ML SYRP 473 ML BOTTLE $2.39 ALBUTEROL 2.5 MG /3 ML (0.083 %) NEBU 3 ML VIAL $11.92 ALBUTEROL 90 MCG/ACTUATION HFAA 18 G CANISTER $504.93 ALBUTEROL 90 MCG/ACTUATION HFAA 6.7 G CANISTER $727.19 ALBUTEROL 90 MCG/ACTUATION HFAA 8 G CANISTER $189.70 ALBUTEROL 90 MCG/ACTUATION HFAA 8.5 G CANISTER $543.22 ALCOHOL 98 % SOLN 5 ML AMPUL $1,082.05 ALCOHOL 98 % SOLN 5 ML VIAL $768.06 ALCOHOL-ETHYL, URINE 80320 $342.00 ALCOHOLS LEVELS 80322 $246.00 ALDOSTERONE SUPPRESSION EVALUATION PANEL 80408 $982.00 ALENDRONATE 10 MG TAB 100 EACH BOTTLE $11.12 ALENDRONATE 10 MG TAB 20 EACH BLIST PACK $22.21 ALENDRONATE 70 MG TAB 12 EACH BLIST PACK $11.06 ALENDRONATE 70 MG TAB 20 EACH BLIST PACK $16.25 ALFENTANIL 500 MCG/ML SOLN 2 ML AMPUL $31.92 ALFENTANIL 500 MCG/ML SOLN 5 ML AMPUL $28.67 ALFUZOSIN 10 MG TB24 100 EACH BOTTLE $26.87 ALIGNMENT OF KNEE JOINT UNDER ANESTHESIA 27570 $5,063.00 ALISKIREN 150 MG TAB 30 EACH BOTTLE $54.69 ALLERGENS, EA (RAST) 86003 $49.00 ALLOPURINOL 100 MG TAB 100 EACH BLIST PACK $2.87 ALLOPURINOL 300 MG TAB 100 EACH BLIST PACK $5.76 ALLOPURINOL 500 MG SOLR 1 EACH VIAL $43,634.37 ALPRAZOLAM 0.25 MG TAB 1 EACH BLIST PACK $4.96 LCMC Health is committed to helping patients understand and prepare for the cost of their care. LCMC Health provides a list of charges for services provided at our facilities; however, a patient’s out-of-pocket responsibility for these charges will vary, depending on their insurance coverage and benefit plan. We understand that it is confusing for a patient to navigate through the many factors involved in their final cost. Please contact our Financial Assistance staff at 504.702.3500 with any questions about a future service or a bill you have received.
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • Neonatal Intensive Care Drug Therapy Update: a Bibliography
    LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 J Perinat Neonat Nurs Vol. 18, No. 3, pp. 292–306 c 2004 Lippincott Williams & Wilkins, Inc. Neonatal Intensive Care Drug Therapy Update: A Bibliography Jason Sauberan, PharmD BIBLIOGRAPHY I. Overview A. Clark RH, Bloom BT, Gerstmann DR Medications Used in Neonatal Intensive Care Units—A Descriptive Study [abstract 3047]. In: Program and abstracts of the 2004 Pediatric Academic Societies’ Annual Meeting, San Francisco, CA. B. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002 Feb;19(2):67–72. C. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002 Nov;110(5):e52. D. Committee on Drugs. American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002 Jul;110(1 Pt 1):181–3. II. Anti-infectives A. Linezolid 1. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S158–63. 2. Vo M, Cirincione BB, Rubino CM, Jungbluth GL. Pharmacokinetics of Linezolid in Neonates and Young Infants [abstract A-1409]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
    [Show full text]
  • Application and Review of Pediatric Pharmacotherapy, Sample Chapter
    Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 Section 1 Neonatal intensive care “Luck is where preparation meets opportunity.” This section consists of 16 medication orders followed by corresponding patient profiles representing pharmacotherapy associated with patients admit- ted to a neonatal intensive care unit. Each patient profile is followed by multiple-choice questions pertaining to the medication order and profile infor- mation. Choose the one best-lettered response to each item. The correct answers are provided at the end of this section. The reader is encouraged to attempt all questions for each case or for the entire section prior to referring to the answers. Moreover, where appropriate, the answer key provides a thor- ough explanation of the correct response and should serve as an additional learning tool for the reader. Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 2 | Application and Review of Pediatric Pharmacotherapy Medication orders Physician order Patient weight: 2.5 kg Aminophylline 10 mg iv load, then begin 2.5 mg iv q 12 h Obtain theophylline concentration 1 h postinfusion of loading dose Date/time: 12/01/2100 Patient name: Baby Boy Turner Physician: John Craver Patient ID: 111222 Medical profile Patient: Baby Boy Turner Patient weight: 2.5 kg Age: 1d/o Present illness: Apneic episodes Allergies: None Medical history: 33 weeks gestation, Apgar 7 and 9 Labs: pending Medication profile Questions Q1 Which of the following is an acceptable definition of apnea of prematurity? 1 o cessation of breathing for less than 20 s 2 o cessation of breathing for at least 20 s 3 o cessation of breathing for less than 20 s when accompanied by bradycardia A o 1 only B o 3 only C o 1 and 3 only Application and Review of Pediatric Pharmacotherapy Chapter No.
    [Show full text]
  • Caffeine in the Treatment of Pain
    Rev Bras Anestesiol ARTIGOS DE REVISÃO 2012; 62: 3: 387-401 ARTIGOS DE REVISÃO Cafeína para o Tratamento de Dor Cristiane Tavares, TSA 1, Rioko Kimiko Sakata, TSA 2 Resumo: Tavares C, Sakata RK – Cafeína para o Tratamento de Dor. Justificativa e objetivos: A cafeína é uma substância amplamente consumida com efeitos em diversos sistemas e que apresenta farmacoci- nética e farmacodinâmica características, causando interações com diversos medicamentos. O objetivo deste estudo é fazer uma revisão sobre os efeitos da cafeína. Conteúdo: Nesta revisão, são abordados a farmacologia da cafeína, os mecanismos de ação, as indicações, as contraindicações, as doses, as interações e os efeitos adversos. Conclusões: Faltam estudos controlados, randomizados e duplos-cegos para avaliar a eficácia analgésica da cafeína nas diversas síndromes dolorosas. Em pacientes com dor crônica, é necessário ter cautela em relação ao desenvolvimento de tolerância, abstinência e interação medi- camentosa no uso crônico de cafeína. Unitermos: ANALGESIA; DOR; DROGAS, Alcaloide/cafeína. ©2012 Elsevier Editora Ltda. Todos os direitos reservados. INTRODUÇÃO Estrutura química A cafeína foi isolada em 1820, mas a estrutura correta des- A cafeína é um alcaloide presente em mais de 60 espécies ta metilxantina foi estabelecida na última década do século de plantas 4. Sua estrutura molecular pertence a um grupo XIX. Os efeitos não foram claramente reconhecidos até 1981, de xantinas trimetiladas que incluem seus compostos inti- quando o bloqueio de receptores adenosina foi correlacio- mamente relacionados: teobromina (presente no cacau) e nado às propriedades estimulantes da cafeína e de seus teofilina (presente no chá) 1. Quimicamente, esses alcaloides análogos 1. Provavelmente a cafeína é uma das substâncias são semelhantes a purinas, xantinas e ácido úrico, que são psicoativas mais utilizadas no mundo, promovendo efeitos compostos metabolicamente importantes 4.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Caffeine Citrate 10Mg/Ml Oral Solution Maintenance Doses
    PACKAGE LEAFLET: INFORMATION FOR THE PATIENT doctor or nurse may give one more higher • changes in blood tests (reduced levels dose, before continuing to the lower of haemoglobin after prolonged Caffeine Citrate 10mg/ml Oral Solution maintenance doses. treatment) Duration of treatment • reduced thyroid hormone at the start Equivalent to Caffeine 5mg/ml Your baby’s doctor will decide exactly of treatment with other medicines given at the same Please read all of this leaflet carefully how long your newborn must continue Reporting of side effects time. A premature baby may need many before your baby is given this therapy with Caffeine Citrate 10mg/ml If your newborn gets any side effects, medicines, and any problems with caffeine medicine. Oral Solution. If your baby has 5 to 7 days talk to your baby’s doctor. This includes are likely to be minor, but tell the doctor • Keep this leaflet. You may need to read without apnoea attacks, the doctor will any possible side effects not listed in this about any other medication they may it again. stop treatment. leaflet. You can also report side effects D04359 not know about, particularly any other • If you have further questions, please The doctor may decide to check the directly via Yellow Card Scheme. medicine (for example theophylline) given ask the hospital doctor who is looking levels of caffeine in a blood sample Website: www.mhra.gov.uk/yellowcard to your baby to help it breathe. after your baby. as a precaution, or if your baby is not or search for MHRA Yellow Card in the If your newborn gets any side effects, Medications containing phenobarbitone responding to treatment as expected.
    [Show full text]
  • Nevada Medicaid Formulary
    Nevada Medicaid-Approved Preferred Drug List Effective August 15, 2021 Legend In each class, drugs are listed alphabetically by either brand name or generic name. Brand name drug: Uppercase in bold type Generic drug: Lowercase in plain type AL: Age Limit Restrictions DO: Dose Optimization Program GR: Gender Restriction OTC: Over the counter medication available with a prescription. (Prescribers please indicate OTC on the prescription) PA: Prior authorization is required. Prior authorization is the process of obtaining approval of benefits before certain prescriptions are filled. QL: Quantity limits; certain prescription medications have specific quantity limits per prescription or per month. SP: Specialty Pharmacy ST: Step therapy is required. You may need to use one medication before benefits for the use of another medication can be authorized. Drug Name Reference Notes *ADHD/ANTI-NARCOLEPSY/ANTI- OBESITY/ANOREXIANTS* *ADHD AGENT - SELECTIVE ALPHA ADRENERGIC AGONISTS*** clonidine hcl er oral tablet extended release Kapvay AL; QL 12 hour *ADHD AGENT - SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR*** atomoxetine hcl oral capsule Strattera DO; AL; QL *AMPHETAMINE MIXTURES*** amphetamine-dextroamphet er oral capsule extended release 24 hour 10 mg, 15 mg, 5 Adderall XR DO; AL; QL mg amphetamine-dextroamphet er oral capsule extended release 24 hour 20 mg, 25 mg, 30 Adderall XR AL; QL mg amphetamine-dextroamphetamine oral Adderall DO; AL; QL tablet 10 mg, 12.5 mg, 15 mg, 5 mg, 7.5 mg amphetamine-dextroamphetamine oral Adderall AL tablet 20 mg,
    [Show full text]
  • Acetylsalicylic Acid (375 Mg), Codeine Phosphate (15 Mg), Caffeine (15 Mg*) Tablets
    Prescribing Information INCLUDING PATIENT MEDICATION INFORMATION N.282® Acetylsalicylic Acid (375 mg), Codeine Phosphate (15 mg), Caffeine (15 mg*) Tablets *equivalent to 30 mg caffeine citrate N.292® Acetylsalicylic acid (375 mg), Codeine Phosphate (30 mg), Caffeine (15 mg*) Tablets *equivalent to 30 mg caffeine citrate ANALGESIC - ANTIPYRETIC PENDOPHARM, Division of Pharmascience Inc. Date of Revision: 6111 Royalmount Ave., Suite 100 Montréal, Québec November 23, 2016 H4P 2T4 Submission Control No.: 195437 282 and 292 are registered trademarks of Pharmascience Inc. TABLE OF CONTENT PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................................. 5 ADVERSE REACTIONS ................................................................................................. 12 DRUG INTERACTIONS .................................................................................................. 14 DOSAGE AND ADMINISTRATION .............................................................................. 15 OVERDOSAGE ...............................................................................................................
    [Show full text]
  • Physiological Effects of Caffeine and Its Congeners Present in Tea And
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 2 August 2018 doi:10.20944/preprints201808.0032.v1 1 Type of the paper: Review 2 3 Physiological effects of caffeine and its congeners 4 present in tea and coffee beverages 5 6 I. Iqbal1, M. N. Aftab2, M. A. Safer3, M. Menon4, M. Afzal5⌘ 7 1Department of Life Sciences, Lahore College for Women, Lahore, Pakistan 8 2Institute of Biochemistry and Biotechnology, Government College University, 9 Lahore 54000, Pakistan 10 3Department of Biological Sciences, Faculty of Science, Kuwait University, Kuwait 11 4Plamer University (West Campus) San Jose, CA 12 5Department of Biological Sciences, Faculty of Science, Kuwait University, Kuwait 13 ⌘ Correspondence: [email protected], Tel. +1 352 681 7347 14 15 16 Running title: Caffeine 17 18 19 20 21 22 23 Corresponding author: 24 M. Afzal, 25 10547 NW 14th PL. 26 Gainesville, FL. USA 27 email: [email protected] 28 Tel. +1 352 681 7347 29 30 1 © 2018 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 2 August 2018 doi:10.20944/preprints201808.0032.v1 31 Abstract: Tea and coffee are the most commonly used beverages throughout the 32 world. Both decoctions are rich in small organic molecules such as 33 phenolics/polyphenolics, purine alkaloids, many methylxanthines, substituted 34 benzoic and cinnamic acids. Many of these molecules are physiologically 35 chemopreventive and chemoprotective agents against many severe conditions such 36 as cancer, Alzheimer, Parkinsonism, inflammation, sleep apnea, cardiovascular 37 disorders, bradycardia, fatigue, muscular relaxation, and oxidative stress.
    [Show full text]
  • CPT / HCPCS Code Drug Description Approximate Cost Share
    The information listed here is for our most prevalent plan. The amount you pay for a covered drug will depend on your plan’s coverage. Please refer to your Medical Plan GTB for more information. To find out the cost of your drugs, please contact HMSA Customer Service at 1-800-776-4672. If you receive services from a nonparticipating provider, you are responsible for a copayment plus any difference between the actual charge and the eligible charge. Legend $0 = no cost share $ = $100 and under $$ = over $100 to $250 $$$ = over $250 to $500 $$$$ = over $500 to $1000 $$$$$ = over $1000 1 = Please call HMSA Customer Service 1-800-776-4672 for cost share information. 2 = The cost share for this drug is dependent upon the diagnosis. Please call HMSA Customer Service at 1-800-772-4672 for more information. 3 = Cost share information for these drugs is dependent upon the dose prescribed. Please call HMSA Customer Service at 1- 800-772-4672 for more information. CPT / HCPCS approximate Code Drug Description cost share J0129 Abatacept Injection $$$$ J0130 Abciximab Injection 3 J0131 Acetaminophen Injection $ J0132 Acetylcysteine Injection $ J0133 Acyclovir Injection $ J0135 Adalimumab Injection $$$$ J0153 Adenosine Inj 1Mg $ J0171 Adrenalin Epinephrine Inject $ J0178 Aflibercept Injection $$$ J0180 Agalsidase Beta Injection 3 J0200 Alatrofloxacin Mesylate 3 J0205 Alglucerase Injection 3 J0207 Amifostine 3 J0210 Methyldopate Hcl Injection 3 J0215 Alefacept 3 J0220 Alglucosidase Alfa Injection 3 J0221 Lumizyme Injection 3 J0256 Alpha 1 Proteinase Inhibitor
    [Show full text]
  • Scanned Using Fujitsu 6670 Scanner and Scandall Pro Ver 1.7 Software
    1816 1990/826 THE DRUG TARIFF 1990 PURSUANT to section 99 of the Social Security Act 1964, the Minister of Health hereby gives the following direction. ANALYSIS I. Title and commencement 15. Disputes 2. Interpretation PART I PART III GENERAL RULES AFFECTING DIRECTION MISCELLANEOUS PROVISIONS 3. Scope of direction 16. Claims on Department 4. Standards I 7. Allergy treatment sets 5. Charges for requirements 18. Payment for non·disposable syringes and needles PART 11 19. Payment for plastic syringes RULES FOR PRICING 20. Period and quantity of supply for 6. Calculation of payments doctors' and midwives' prescriptions 7. Application of Pricing Schedules 21. Period and quantity of supply for 8. Computation of selling price prescriptions for oral contraceptives 9. Rounding calculations 22. Period and quantity of supply for 10. Minimum charges dentist's prescriptions 11. Adjustment of dose volumes of oral 23. Original packs, and certain antibiotics liquid requirements 24. Bulk supply orders 12. Water 25. Practitioner's supply orders 13. Payment for bulk supply orders 26. Wholesale supply orders 14. Payment for practitioners' supply 27. Revocations and savings orders Schedule DIRECTION 1. Tide and commencement-(I) This direction may be cited as the Drug Tariff 1990. (2) This direction shall come into force on the 1st day of December 1990. 2. Interpretation-(1) In this direction, unless the context otherwise requires,- "The Act" means the Social Security Act 1964: "Board" means an Area Health Board under the Area Health Boards Act 1983 or a Hospital
    [Show full text]
  • Skin Aging Handbook
    SKIN AGING HANDBOOK An Integrated Approach to Biochemistry and Product Development Edited by Nava Dayan Norwich, NY, USA Copyright © 2008 by William Andrew Inc. No part of this book may be reproduced or utilized in any form or by any means, electronic or me- chanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the Publisher. ISBN: 978-0-8155-1584-5 Library of Congress Cataloging-in-Publication Data Skin aging handbook : an integrated approach to biochemistry and product development / edited by Nava Dayan. p. ; cm. -- (Personal care and cosmetic technology) Includes bibliographical references and index. ISBN 978-0-8155-1584-5 (alk. paper) 1. Skin--Aging. 2. Cosmetics. 3. Dermatologic agents. 4. Cosmetic industry. 5. Dermatologic agents industry. I. Dayan, Nava. II. Series. [DNLM: 1. Skin Physiology--drug effects. 2. Aging--drug effects. 3. Chemistry, Pharmaceutical. 4. Cosmetics--economics. 5. Cosmetics--pharmacology. 6. Cosmetics--therapeutic use. WR 102 S62715 2008] QP88.5.S553 2008 612.7’9--dc22 2008009757 Printed in the United States of America This book is printed on acid-free paper. 10 9 8 7 6 5 4 3 2 1 Published by: William Andrew Inc. 13 Eaton Avenue Norwich, NY 13815 1-800-932-7045 www.williamandrew.com Cover Design by Russell Richardson ENVIRONMENTALLY FRIENDLY This book has been printed digitally because this process does not use any plates, ink, chemicals, or press solutions that are harmful to the environment. The paper used in this book has a 30% recycled content. NOTICE To the best of our knowledge the information in this publication is accurate; however the Publisher does not assume any responsibility or liability for the accuracy or completeness of, or consequences arising from, such information.
    [Show full text]